MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
OPKO Health Net Debt 2011-2026 | OPK
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -411 M | -75.2 M | -132 M | 82.2 M | 163 M | 184 M | 108 M | 55.3 M | -73.5 M | -58.1 M | 50.4 M | 41.9 M | -4.68 M | -62.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 184 M | -411 M | -9.48 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Medpace Holdings
MEDP
|
-360 M | $ 460.74 | 0.83 % | $ 13.3 B |  USA |
 |
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Bioventus
BVS
|
231 M | $ 9.15 | 1.67 % | $ 610 M | USA |
|
Biodesix
BDSX
|
14.5 M | $ 15.54 | 5.79 % | $ 2.02 B | USA |
 |
Myriad Genetics
MYGN
|
115 M | $ 4.61 | -1.07 % | $ 427 M | USA |
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
National Research Corporation
NRC
|
71.3 M | $ 17.44 | -0.4 % | $ 390 M | USA |
 |
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M |  Israel |
 |
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
-10.9 M | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
-11.9 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Pacific Biosciences of California
PACB
|
-6.67 M | $ 1.39 | - | $ 417 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
1.98 B | $ 159.19 | 0.75 % | $ 7.89 B | USA |
 |
IQVIA Holdings
IQV
|
12 B | $ 166.09 | -0.52 % | $ 28.6 B | USA |
 |
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
Personalis
PSNL
|
-48.8 M | $ 7.78 | 2.23 % | $ 461 M | USA |
 |
Invitae Corporation
NVTA
|
-239 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
1.19 M | $ 1.18 | -19.18 % | $ 6.43 M | USA |
 |
Mettler-Toledo International
MTD
|
2.06 B | $ 1 264.46 | 1.94 % | $ 26.1 B |  Schweiz |
 |
Interpace Biosciences
IDXG
|
105 K | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
Illumina
ILMN
|
-494 M | $ 125.98 | 1.77 % | $ 20 B | USA |
 |
RadNet
RDNT
|
359 M | $ 59.87 | -3.03 % | $ 4.5 B | USA |
 |
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B |  Niderland |
 |
Precipio
PRPO
|
-1.18 M | $ 26.6 | -1.23 % | $ 34.5 M | USA |
 |
Senseonics Holdings
SENS
|
-4.15 M | $ 6.66 | 0.6 % | $ 278 M | USA |
 |
Sotera Health Company
SHC
|
1.79 B | $ 13.84 | -0.32 % | $ 3.93 B | USA |
 |
Celcuity
CELC
|
82.8 M | $ 102.01 | -4.44 % | $ 4.02 B | USA |
 |
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
4.74 B | $ 266.12 | 0.64 % | $ 22.1 B | USA |
 |
Soleno Therapeutics
SLNO
|
-19.5 M | $ 31.34 | -1.2 % | $ 1.59 B | USA |
 |
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | Israel |
 |
ENDRA Life Sciences
NDRA
|
-4.37 M | $ 3.46 | -0.57 % | $ 1.86 M | USA |
 |
NeoGenomics
NEO
|
187 M | $ 7.86 | -2.96 % | $ 1.01 B | USA |
 |
Neuronetics
STIM
|
-46.7 M | $ 1.46 | -9.06 % | $ 96.3 M | USA |
 |
Natera
NTRA
|
-177 M | $ 194.52 | -2.78 % | $ 19.1 B | USA |
 |
CareDx, Inc
CDNA
|
-39.2 M | $ 17.84 | 1.59 % | $ 951 M | USA |
 |
Castle Biosciences
CSTL
|
-108 M | $ 25.35 | -1.55 % | $ 704 M | USA |
 |
DarioHealth Corp.
DRIO
|
9.37 M | $ 7.76 | 3.47 % | $ 30.9 M | Israel |
 |
DexCom
DXCM
|
-842 M | $ 66.6 | 1.0 % | $ 26 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-916 M | $ 104.91 | - | $ 19.8 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-107 M | $ 47.49 | 6.72 % | $ 2.84 B | USA |